Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19
vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2
messenger RNA (mRNA) COVID-19 vaccine in patients with CLL and compared responses
with those obtained in age-matched healthy control subjects. Patients received 2 vaccine
doses, 21 days apart, and antibody titers were measured by using the Elecsys Anti-SARS …

Background: Antibody response following SARS-CoV-2 vaccination is somewhat defective
in chronic lymphocytic leukemia (CLL). Moreover, the correlation between serologic
response and status of cellular immunity has been poorly studied. Objective: This study was
undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger
RNA (mRNA) COVID-19 vaccination in CLL. Methods: The presence of the spike antibodies
was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV-2 in …